| HOME >> BIOLOGY >> TECHNOLOGY |
NEW YORK, Sept. 3 /PRNewswire/ -- Exosome Diagnostics, Inc. today announced additions to its management team as the company moves forward with development of its blood-based diagnostics that can identify cancer-specific genetic mutations.
Wayne D. Comper, Ph.D., D.Sc., has joined Exosome Diagnostics as the chief scientific officer. Dr. Comper has extensive experience both as a biotechnology executive and as a biomedical research scientist. Prior to joining Exosome, he was chief science officer of AusAm Biotechnologies, Inc., a company developing diagnostics and therapeutics to identify and treat kidney, cardiovascular and infectious diseases. Dr. Comper has also published over 160 articles in peer-reviewed international journals. Dr. Comper received both his Ph.D. and D.Sc. from Monash University, Clayton, Victoria, Australia.
Tom Tsakeris has been appointed director of regulatory affairs. Mr. Tsakeris' expertise includes extensive experience with the Food and Drug Administration (FDA) and as an advisor to companies on the regulatory approval process. Prior to joining Exosome, Mr. Tsakeris was president of Devices and Diagnostics Consulting Group, Inc. His prior positions also include director of the Division of Clinical Laboratory Devices, Office of Device Evaluation, Center for Devices and Radiological Health and several other management roles at FDA. During his tenure at FDA, he played a key role in developing the implementation strategy for the Clinical Laboratory Improvement Act (CLIA) of 1988.
"With our exosome technology, we are able to overcome a fundamental
issue of how to capture diagnostic quantities of genetic mutations in
blood," said James McCullough, chairman & chief executive officer. "These
mutations contain enormous amounts of information specific to different
types of cancers that can be used for diagnosis and disease monitoring.
These important management additions will now enable us to expand clinical
development of o
'/>"/>
| SOURCE Exosome Diagnostics, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
2. Strategic Diagnostics Updates Roth Conference Presentation Time
3. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
4. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
5. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
6. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
7. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
8. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
9. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
10. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
11. Roche Diagnostics Launches CoaguChek XS Plus System to Provide New PT/INR Point-of-Care Solution for Non-Waived Anticoagulation Services
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |